Skip to content
2000
Volume 20, Issue 6
  • ISSN: 1574-8855
  • E-ISSN: 2212-3903

Abstract

Remimazolam, a novel ultra-short-acting benzodiazepine, has emerged as a promising agent in the field of anaesthesia and sedation. This comprehensive review examines the pharmacological properties, clinical applications, and safety profile of remimazolam. Its unique pharmacokinetic profile, characterised by rapid onset and offset of action, organ-independent metabolism, and availability of a specific reversal agent, offers potential advantages over traditional sedatives. Clinical studies have demonstrated its efficacy in procedural sedation, particularly in gastrointestinal endoscopy and bronchoscopy, as well as in the induction and maintenance of general anaesthesia. Emerging evidence also suggests its potential utility in intensive care sedation. Remimazolam has shown a favourable safety profile, with studies indicating comparable or improved hemodynamic stability and potentially reduced respiratory depression compared to propofol. The availability of flumazenil as a reversal agent enhances its safety profile. However, as with any relatively new medication, ongoing research is needed to fully characterise its long-term safety and optimal use in various clinical scenarios. This review synthesises current knowledge on remimazolam, providing insights into its potential to optimise sedation and anaesthesia practices across diverse patient populations and clinical settings, while highlighting areas for future research.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855346302241227031649
2025-01-20
2025-10-23

  • From This Site

    /content/journals/cdth/10.2174/0115748855346302241227031649
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SaariT.I. OukariU.M. AhonenJ. OlkkolaK.T. Enhancement of GABAergic activity: Neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology.Pharmacol. Rev.201163124326710.1124/pr.110.00271721245208
     [Google Scholar]
  2. GoudraB. SinghP. Remimazolam: The future of its sedative potential.Saudi J. Anaesth.20148338839110.4103/1658‑354X.13662725191193
     [Google Scholar]
  3. KilpatrickG.J. McIntyreM.S. CoxR.F. StaffordJ.A. PacofskyG.J. LovellG.G. WiardR.P. FeldmanP.L. CollinsH. WaszczakB.L. TilbrookG.S. CNS 7056: A novel ultra-short-acting benzodiazepine.Anesthesiology20071071606610.1097/01.anes.0000267503.85085.c017585216
     [Google Scholar]
  4. KimK.M. Remimazolam: Pharmacological characteristics and clinical applications in anesthesiology.Anesth. Pain Med.202217111110.17085/apm.2111535139608
     [Google Scholar]
  5. WangM. ZhaoX. YinP. BaoX. TangH. KangX. Profile of remimazolam in anesthesiology: A narrative review of clinical research progress.Drug Des. Devel. Ther.2022163431344410.2147/DDDT.S37595736213379
     [Google Scholar]
  6. ChenG.C. LinS.S. LinP.A. TsengW.C. LuC.H. A narrative review of remimazolam in procedural sedation.Asian J. Anesthesiol.2023612394510.6859/aja.202306_61(2).000137386924
     [Google Scholar]
  7. LeeA. ShirleyM. Remimazolam: A review in procedural sedation.Drugs202181101193120110.1007/s40265‑021‑01544‑834196946
     [Google Scholar]
  8. National Center for Biotechnology InformationPubchem compound summary for CID9867812, Remimazolam.Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Remimazolam (Accessed on: Nov 2).2024
  9. PandharipandeP. Hughes McGrane Sedation in the intensive care setting.Clin. Pharmacol.20124536310.2147/CPAA.S2658223204873
     [Google Scholar]
  10. KeerthyH.P. BalakrishnaR. SrungeriK.M. SinghviN. JohnJ. IslamM. Comparitive evaluation of propofol and midazolam as conscious sedatives in minor oral surgery.J. Maxillofac. Oral Surg.201514377378310.1007/s12663‑014‑0676‑y26225076
     [Google Scholar]
  11. McKeageK. PerryC.M. Propofol.CNS Drugs200317423527210.2165/00023210‑200317040‑0000312665397
     [Google Scholar]
  12. DevlinJ.W. LauA.K. TaniosM.A. Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: An analysis of frequency and risk factors.Pharmacotherapy200525101348135210.1592/phco.2005.25.10.134816185179
     [Google Scholar]
  13. BauerT.M. RitzR. HaberthürC. HaefeliW.E. LavizzariS.G. HaH.R. HunkelerW. SleightA.J. Prolonged sedation due to accumulation of conjugated metabolites of midazolam.Lancet1995346896814514710.1016/S0140‑6736(95)91209‑67603229
     [Google Scholar]
  14. SpinaS.P. EnsomM.H.H. Clinical pharmacokinetic monitoring of midazolam in critically ill patients.Pharmacotherapy200727338939810.1592/phco.27.3.38917316150
     [Google Scholar]
  15. BarrJ. DonnerA. Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit.Crit. Care Clin.199511482784710.1016/S0749‑0704(18)30041‑18535981
     [Google Scholar]
  16. ChenH. WangX. LuY. TangS. DingT. SongJ.C. ChenG. Comparison of the recovery time of remimazolam besylate and propofol for gastrointestinal endoscopy sedation in elderly patients.Int. J. Med. Sci.20242171250125610.7150/ijms.9304538818475
     [Google Scholar]
  17. LuK. WeiS. LingW. WeiY. RanX. HuangH. WangM. WeiN. LiaoY. QinZ. PanM. WeiQ. FuL. XiongB. MaC. JiangJ. HuangY. Remimazolam versus propofol for deep sedation/anaesthesia in upper gastrointestinal endoscopy in elderly patients: A multicenter, randomized controlled trial.J. Clin. Pharm. Ther.202247122230223610.1111/jcpt.1379736334013
     [Google Scholar]
  18. ChenS.H. YuanT.M. ZhangJ. BaiH. TianM. PanC.X. BaoH.G. JinX.J. JiF.H. ZhongT.D. WangQ. LvJ.R. WangS. LiY.J. YuY.H. LuoA.L. LiX.K. MinS. LiL. ZouX.H. HuangY.G. Remimazolam tosilate in upper gastrointestinal endoscopy: A multicenter, randomized, non‐inferiority, phase III trial.J. Gastroenterol. Hepatol.202136247448110.1111/jgh.1518832677707
     [Google Scholar]
  19. BorkettK.M. RiffD.S. SchwartzH.I. WinkleP.J. PambiancoD.J. LeesJ.P. OgunbiyiW.K. A Phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy.Anesth. Analg.2015120477178010.1213/ANE.000000000000054825502841
     [Google Scholar]
  20. ChenQ. QinB. ZhangM. ZhouY. ShiX. XieY. The safety and efficacy of remimazolam compared to dexmedetomidine for awake tracheal intubation by flexible bronchoscopy: A randomized, double-blind, controlled trial.Drug Des. Devel. Ther.20241896797810.2147/DDDT.S44622238562518
     [Google Scholar]
  21. WuQ. XuR. ZhouX. WangL. ShengC. DingM. CaoY. Bolus administration of remimazolam was superior to midazolam for deep sedation in elderly patients undergoing diagnostic bronchoscopy: A randomized, double-blind, controlled trial.Medicine (Baltimore)202410312e3721510.1097/MD.000000000003721538518001
     [Google Scholar]
  22. PastisN.J. YarmusL.B. SchippersF. OstroffR. ChenA. AkulianJ. WahidiM. ShojaeeS. TannerN.T. CallahanS.P. FeldmanG. LorchD.G.Jr NdukwuI. PritchettM.A. SilvestriG.A. Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy.Chest2019155113714610.1016/j.chest.2018.09.01530292760
     [Google Scholar]
  23. DongS.A. GuoY. LiuS.S. WuL.L. WuL.N. SongK. WangJ.H. ChenH.R. LiW.Z. LiH.X. ZhangL. YuJ.B. A randomized, controlled clinical trial comparing remimazolam to propofol when combined with alfentanil for sedation during ERCP procedures.J. Clin. Anesth.20238611107710.1016/j.jclinane.2023.11107736764022
     [Google Scholar]
  24. PAION announces submission of the marketing authorization application for remimazolam in procedural sedation to the european medicines agency.Available from: https://www.paion.com/ (Accessed on: Nov 05).2024
  25. KeamS.J. Remimazolam: First approval.Drugs202080662563310.1007/s40265‑020‑01299‑832274703
     [Google Scholar]
  26. PAION AGMundipharma receives market approval for Anerem® (remimazolam) in general anesthesia in Japan.Available from: https://www.paion.com/ (Accessed on: Nov 05).2024
  27. PAION AGByfavo® (remimazolam) approved by MHRA for general anesthesia in adults.Available from: https://www.paion.com/en/news/ [Cited on: Nov 5].2024
  28. BrohanJ. GoudraB.G. The role of GABA receptor agonists in anesthesia and sedation.CNS Drugs2017311084585610.1007/s40263‑017‑0463‑729039138
     [Google Scholar]
  29. UptonR.N. MartinezA.M. GrantC. A dose escalation study in sheep of the effects of the benzodiazepine CNS 7056 on sedation, the EEG and the respiratory and cardiovascular systems.Br. J. Pharmacol.20081551526110.1038/bjp.2008.22818552878
     [Google Scholar]
  30. BaiC. XuM. GuoY. JinY. ZhaoX. Clinical application and research progress of remimazolam for pediatric patients.Drug Des. Devel. Ther.2024181221122910.2147/DDDT.S45344038645987
     [Google Scholar]
  31. WiltshireH.R. KilpatrickG.J. TilbrookG.S. BorkettK.M. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.Anesth. Analg.2012115228429610.1213/ANE.0b013e318241f68a22253270
     [Google Scholar]
  32. ZhouY. HuP. JiangJ. Metabolite characterization of a novel sedative drug, remimazolam in human plasma and urine using ultra high-performance liquid chromatography coupled with synapt high-definition mass spectrometry.J. Pharm. Biomed. Anal.2017137788310.1016/j.jpba.2017.01.01628104560
     [Google Scholar]
  33. BirgenheierN.M. StuartA.R. EganT.D. Soft drugs in anesthesia: Remifentanil as prototype to modern anesthetic drug development.Curr. Opin. Anaesthesiol.202033449950510.1097/ACO.000000000000087932530892
     [Google Scholar]
  34. WorthingtonM.T. AntonikL.J. GoldwaterD.R. LeesJ.P. OgunbiyiW.K. BorkettK.M. MitchellM.C. A phase Ib, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy.Anesth. Analg.201311751093110010.1213/ANE.0b013e3182a705ae24108261
     [Google Scholar]
  35. SchüttlerJ. EisenriedA. LerchM. FechnerJ. JeleazcovC. IhmsenH. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers.Anesthesiology2020132463665110.1097/ALN.000000000000310331972655
     [Google Scholar]
  36. NoorN. LegendreR. CloutetA. ChitneniA. VarrassiG. KayeA.D. A comprehensive review of remimazolam for sedation.Health Psychol. Res.2021912451410.52965/001c.2451434746482
     [Google Scholar]
  37. LeeJ. JeongS. LeeD.H. ParkJ.S. Finding the ideal sedative: A non‐inferiority study of remimazolam vs propofol in endoscopic retrograde cholangiopancreatography.J. Gastroenterol. Hepatol.202338122160216610.1111/jgh.1635437730240
     [Google Scholar]
  38. DoiM. MoritaK. TakedaJ. SakamotoA. YamakageM. SuzukiT. Efficacy and safety of remimazolam versus propofol for general anesthesia: A multicenter, single-blind, randomized, parallel-group, phase IIb/III trial.J. Anesth.202034454355310.1007/s00540‑020‑02788‑632417976
     [Google Scholar]
  39. LanH. CaoH. LiuS. GongX. HuangX. RongH. XuB. ChenH. JiaoZ. LinY. GuanX. Efficacy of remimazolam tosilate versus propofol for total intravenous anaesthesia in urological surgery.Eur. J. Anaesthesiol.202441320821610.1097/EJA.000000000000193838165145
     [Google Scholar]
  40. KimH.J. KimJ.Y. ParkH.S. KimH. RoY.J. KohW.U. Effect of remimazolam- versus propofol-based total intravenous general anesthesia on intraoperative hemodynamic stability for major spine surgery in the prone position: A randomized controlled trial.Medicina202460343210.3390/medicina6003043238541158
     [Google Scholar]
  41. ZhangX. LiS. LiuJ. Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: Single-centre randomized controlled trial.BMC Anesthesiol.202121115610.1186/s12871‑021‑01373‑y34016045
     [Google Scholar]
  42. DoiM. HirataN. SuzukiT. MorisakiH. MorimatsuH. SakamotoA. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): Results of a multicenter, randomized, double-blind, parallel-group comparative trial.J. Anesth.202034449150110.1007/s00540‑020‑02776‑w32303884
     [Google Scholar]
  43. ZhaoY. HuangK. HouG. YaoL. LuL. XuS. LianY. YaoZ. YuZ. Efficacy and safety of remimazolam-based sedation for intensive care unit patients undergoing upper gastrointestinal endoscopy: A cohort study.World J. Emerg. Med.2023141313610.5847/wjem.j.1920‑8642.2023.02036713335
     [Google Scholar]
  44. TangY. YangX. ShuH. YuY. XuJ. PanS. ZouX. YuanS. ShangY. Remimazolam besylate for sedation of postoperative patients in intensive care units: A phase I, open label, dose-finding study.Chin. Med. J.2022135172134213610.1097/CM9.000000000000224336191588
     [Google Scholar]
  45. TangY. GaoX. XuJ. RenL. QiH. LiR. ShuH. ZouX. YuanS. YangX. ShangY. Remimazolam besylate versus propofol for deep sedation in critically ill patients: A randomized pilot study.Crit. Care202327147410.1186/s13054‑023‑04760‑838049909
     [Google Scholar]
  46. YaoZ. LiaoZ. LiG. WangL. ZhanL. XiaW. Remimazolam tosylate’s long-term sedative properties in ICU patients on mechanical ventilation: Effectiveness and safety.Eur. J. Med. Res.202328145210.1186/s40001‑023‑01440‑937865799
     [Google Scholar]
  47. YoshikawaH. HosokawaM. KashimaY. OkiS. MasuiK. Remimazolam tolerance in long-term benzodiazepine users: A case report of 2 cases.A A Pract.2021155e0146010.1213/XAA.000000000000146033988524
     [Google Scholar]
  48. WuQ. XuF. WangJ. JiangM. Comparison of remimazolam–flumazenil versus propofol for recovery from general anesthesia: A systematic review and meta-analysis.J. Clin. Med.20231223731610.3390/jcm1223731638068368
     [Google Scholar]
  49. ChenX. SangN. SongK. ZhongW. WangH. JiangJ. HuangY. HuP. Psychomotor recovery following remimazolam-induced sedation and the effectiveness of flumazenil as an antidote.Clin. Ther.202042461462410.1016/j.clinthera.2020.02.00632178858
     [Google Scholar]
  50. KempenaersS. HansenT.G. VeldeV.D.M. Remimazolam and serious adverse events.Eur. J. Anaesthesiol.2023401184185310.1097/EJA.000000000000190237727906
     [Google Scholar]
  51. IoT. SaundersR. PesicM. PetersenK.U. StoehrT. A miniature pig model of pharmacological tolerance to long-term sedation with the intravenous benzodiazepines; midazolam and remimazolam.Eur. J. Pharmacol.202189617388610.1016/j.ejphar.2021.17388633493482
     [Google Scholar]
  52. KitauraA. HamasakiS. SakamotoH. TsukimotoS. NakajimaY. Two cases of inadequate response to remimazolam.Cureus2023157e4257610.7759/cureus.4257637637571
     [Google Scholar]
  53. KawashimaS. KinoshitaH. KawashimaW. NakajimaY. Electroencephalogram inability to detect intraoperative awakening in a patient with remimazolam tolerance.Minerva Anestesiol.202389548248310.23736/S0375‑9393.22.16994‑436383081
     [Google Scholar]
  54. SchippersF. PesicM. SaundersR. BorkettK. SearleS. WebsterL. StoehrT. Randomized crossover trial to compare abuse liability of intravenous remimazolam versus intravenous midazolam and placebo in recreational central nervous system depressant users.J. Clin. Pharmacol.20206091189119710.1002/jcph.161432495449
     [Google Scholar]
  55. SasakiH. HoshijimaH. MizutaK. Ringer’s acetate solution-induced precipitation of remimazolam.Br. J. Anaesth.20211263e87e8910.1016/j.bja.2020.11.02133358048
     [Google Scholar]
  56. KilpatrickG.J. Remimazolam: Non-clinical and clinical profile of a new sedative/anesthetic agent.Front. Pharmacol.20211269087510.3389/fphar.2021.69087534354587
     [Google Scholar]
/content/journals/cdth/10.2174/0115748855346302241227031649
Loading
Remimazolam in Modern Anaesthesia Practice: From Pharmacokinetics to Clinical Outcomes
Curr Drug Ther 20, 792 (2025); https://doi.org/10.2174/0115748855346302241227031649
/content/journals/cdth/10.2174/0115748855346302241227031649
/content/journals/cdth/10.2174/0115748855346302241227031649
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): general anaesthesia; intensive care sedation; intravenous anaesthetic; new anaesthetic agent; procedural sedation; Remimazolam; soft drug

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test